Related by context. All words. (Click for frequent words.) 79 Peginterferon 78 Improves Outcomes 78 Meets Primary Endpoint 78 Pooled Analysis 77 Treatment Naive Patients 77 Oral Fingolimod 77 Mg Usa 77 Patients Receiving 77 Investigational Treatment 76 Drug Shows Promise 76 Mg Uk 76 Renal Cell Carcinoma 76 Shows Promise Against 76 Hormone Refractory Prostate Cancer 76 Antitumor Activity 76 Complicated Skin 76 Advanced Melanoma 75 Relapsed Refractory 75 Drug Combo 75 Metastatic Prostate Cancer 75 Treatment Shows Promise 75 Metastatic Melanoma 75 Infected Patients 75 Treatment Reduces 75 Improves Survival 75 Refractory Hodgkin Lymphoma 75 Chronic Hepatitis C 75 Drug Prevents 75 Secondary Hyperparathyroidism 75 Patients Treated With 75 Demonstrates Positive 74 Slow Progression 74 relapsed MM 74 Pegylated Interferon 74 Prolongs Survival 74 erlotinib Tarceva ® 74 Single Dose 74 Initiates Clinical Trial 74 Adjuvant Treatment 74 Treated Patients 74 Hormone Receptor Positive 74 Atypical Hemolytic Uremic Syndrome 74 Nilotinib 74 Autologous Stem Cell Transplantation 74 Phase 2b Clinical Trial 74 Previously Treated 74 Previously Untreated 74 Renal Impairment 74 Achieves Primary Endpoint 74 Aflibercept 74 Novel Oral 74 Chronic HCV 74 Phase 2b Trial 73 Disease Progression 73 ritonavir boosted 73 Treatment Naïve 73 Study Shows Promise 73 Adefovir 73 FUSILEV enhances 73 Anthracycline 73 Elderly Patients 73 Viral Load 73 Myelodysplastic Syndrome MDS 73 Peginterferon Alfa 2a 73 Transdermal Patch 73 CYT# potent vascular disrupting 73 dasatinib Sprycel ® 73 LymphoStat B belimumab 73 alfa 2a 73 Pharmacokinetics PK 73 Lung Cancer Survival 73 Follicular Lymphoma 73 ACE Inhibitors 73 Initiate Clinical Trial 73 Appears Safe 73 myelodysplastic myeloproliferative diseases 73 Premenopausal Women 73 Chronic Sinusitis 73 Rheumatoid Arthritis Patients 73 FDA Okays 73 Diabetic Foot Ulcer 73 CTAP# 73 Desvenlafaxine Succinate 72 HER2 Positive Breast Cancer 72 Patients Undergoing 72 Combination REOLYSIN R 72 Neovascular Age Related Macular 72 Improved Survival 72 dasatinib Sprycel 72 kidney urologic 72 Newly Diagnosed Multiple Myeloma 72 Fludarabine 72 Pediatric Patients 72 Polymerase Inhibitor 72 Mouse Model 72 Valopicitabine 72 Rheumatoid Arthritis Drug 72 Demonstrated Significant 72 Soft Tissue Sarcoma 72 Tipranavir 72 Hypertensive Patients 72 Poorly Controlled 72 Randomized Double Blind 72 Slows Progression 72 Bone Marrow Cells 72 Drug Candidate 72 Intravitreal 72 CYP#A# CYP#D# 72 Phase III Clinical Trial 72 Amgen Neulasta R 72 Combination Treatment 72 Survival Benefit 72 Gene Linked 72 Tumor Response 72 Ribavirin causes 72 Melphalan 72 Lung Cancer Patients 72 Anti Tumor 72 R lenalidomide 72 INTEGRILIN R 72 Chronic Hepatitis B 72 Progressive Multifocal Leukoencephalopathy 72 Phase IIb Trial 72 Protease Inhibitor 72 evaluating picoplatin 72 See CLINICAL PHARMACOLOGY 72 Eculizumab 72 brand ciclesonide HFA 72 Sapacitabine 72 Relapsing Multiple Sclerosis 72 Blood Pressure Drug 72 Myeloma Patients 72 metastatic malignant 72 Test Detects 72 humanized therapeutic 72 Vitrasert R 72 Successfully Treated 72 Anti Tumor Activity 72 Lymphocytic 72 Natalizumab 72 Dose Escalation 72 Lupus Nephritis 72 Tyrosine Kinase Inhibitor 72 Patients Suffering 72 Subtypes 72 Chronic Myeloid Leukemia 72 Reduces Pain 72 Demonstrates Efficacy 72 Vaccine Adjuvant 72 Relapsed Multiple Myeloma 72 Demonstrates Potent 72 Newly Diagnosed Patients 72 Androgen Deprivation Therapy 72 Hypertrophy 72 Heart Failure Patients 72 Study Evaluating 72 Initiates Enrollment 72 Leukemias 72 Breast Cancer Recurrence 72 Randomized Phase 72 Clot Busting 72 Shows Efficacy 71 Associated Adipose Redistribution 71 Completes Patient Enrollment 71 Treatment Experienced 71 Knee Osteoarthritis 71 Unfractionated Heparin 71 FDA Approves Drug 71 Nebulized 71 HER2 Positive 71 Serious Infections 71 IMiDs ® 71 TNF Tumor Necrosis Factor 71 Shows Promising 71 Long Term Efficacy 71 Gene Mutation 71 Advanced Prostate Cancer 71 Rigel R# 71 Adjuvant Chemotherapy 71 Cholesterol Lowering Drug 71 Lowers Risk 71 NICE Recommends 71 Aggressive Prostate Cancer 71 Adjunctive Therapy 71 Treating Chronic 71 PRN FDA Approves 71 Chemoradiation 71 Seasonal Allergic Rhinitis 71 Phase 2a Trial 71 Allogeneic 71 Vidaza ® 71 Immune Responses 71 refractory chronic lymphocytic 71 Diabetic Neuropathy 71 Ovarian Cancer Patients 71 FOLFOX6 71 Thiazolidinediones 71 Malignant Glioma 71 Resistant Hypertension 71 Clostridium difficile Infection 71 Preclinical Study 71 Contrast Agent 71 PEGylated anti 71 Enlarged Prostate 71 Recurrent Breast Cancer 71 Placebo Controlled Study 71 R Saizen R 71 Albuferon TM 71 Cell Transplants 71 Sustiva efavirenz 71 Improve Survival 71 de novo kidney transplant 71 Stomatitis 71 Interferon Beta 71 HCV Genotype 71 abacavir Ziagen 71 Dasatinib 71 Heart Transplant Recipients 71 ergot derivatives 71 Mylan Receives Approval 71 complement inhibitor eculizumab 71 Prostate Cancer Patients 71 Combo Therapy 71 Monotherapy 71 myocardial infarction ventricular fibrillation 71 Shows Statistically Significant 71 Relapsed Refractory Multiple Myeloma 71 Bone Metastases 71 Predict Risk 71 Decitabine 71 Is Well Tolerated 71 Glatiramer Acetate 71 Efficacy Trial 71 Genes Predict 71 Lupus Drug 71 PEGylated Fab fragment 71 Tacrolimus 71 Philadelphia Chromosome Positive 71 Phase III Trial 71 Hemodialysis Patients 71 galiximab 71 Prospective Randomized 71 Kidney Transplant Patients 71 CYP#A# substrate 71 Inhaled Corticosteroids 71 Cutaneous T 71 Levels Linked 71 ara C 71 stage IIIb IV 71 Myelofibrosis 71 Investigational Agent 71 Nucleoside 71 Juvenile Idiopathic Arthritis 71 Zorbtive TM 71 Well Tolerated 71 Pegloticase 71 Castration Resistant Prostate Cancer 71 Randomized Double blind 71 Nonalcoholic fatty liver 70 Vildagliptin 70 Adjunctive 70 nucleoside naive 70 Successfully Treats 70 recurrent metastatic ovarian cancer 70 Receives Orphan Drug Designation 70 sunitinib Sutent ® 70 lenalidomide Revlimid R 70 Fracture Risk 70 sorafenib tablets 70 Heterozygous Familial Hypercholesterolemia 70 Vaginal Gel 70 Patients Treated 70 HCV Protease Inhibitor 70 Advanced Colorectal Cancer 70 SPRYCEL ® 70 vapreotide acetate 70 Node Positive 70 Paclitaxel Carboplatin 70 Obesity Linked 70 Gastric Cancer 70 Pivotal Phase 70 Prostate Biopsy 70 Virus Linked 70 Vaccine Candidate 70 Phase 2a Clinical Trial 70 Immunotherapeutic 70 Hepatitis C Patients 70 HGS ETR1 mapatumumab 70 adalimumab Humira 70 Protein Linked 70 Tumor Growth 70 intravesical infusion therapy 70 ® lenalidomide 70 chronic eosinophilic leukemia 70 Osteoporosis Drugs 70 Demonstrates Significant 70 Plus Ribavirin 70 COPEGUS R 70 Neoadjuvant 70 FDA Clears 70 Cardiotoxicity 70 recurrent glioblastoma multiforme 70 Treat Heart Failure 70 Disease Modifying 70 Liver Metastases 70 CTAP# Capsules 70 Bosutinib 70 Postmenopausal Women 70 Epilepsy Drug 70 Sleep Disturbances 70 Boceprevir 70 Phase III Trials 70 leukemia AML 70 Capecitabine 70 Pegylated Liposomal Doxorubicin 70 Genes Identified 70 virologically suppressed 70 Plaque Psoriasis 70 Clinical Trial Results 70 antiretroviral naïve 70 Bone Fracture 70 BCG refractory carcinoma 70 First Patient Dosed 70 Adenoviral 70 Phase IIa Clinical Trial 70 Left Ventricular Hypertrophy 70 Azathioprine 70 Randomized Phase II 70 Genes Linked 70 Interferon beta 1a 70 deep venous thromboses 70 Lenalidomide 70 NMIBC 70 unresectable tumors 70 treatment naïve genotype 70 imatinib Gleevec ® 70 Sandostatin R 70 Degarelix 70 mitoxantrone plus 70 thalidomide Thalomid 70 Cytarabine 70 Myelodysplastic Syndromes 70 Multiple Sclerosis Rheumatoid Arthritis 70 EOquin TM phase 70 Phase III Pivotal 70 essential thrombocythemia ET 70 Commercialize Novel 70 Fluorouracil 70 Hyperlipidemia 70 refractory chronic myeloid 70 Drug Resistant 70 Vaccine Shows Promise 70 mild renal insufficiency 70 Severe Sepsis 70 Sustained Efficacy 70 Unresectable 70 Peginterferon alfa 2b 70 Often Misdiagnosed 70 nucleoside analog 70 Inflammatory Markers 70 5 Fluorouracil 70 Safinamide 70 infliximab monotherapy 70 MEK Inhibitor 70 Metastatic Colorectal Cancer 70 BARACLUDE ® 70 Trial Evaluating 70 Investigational Compound 70 Phase 2b Study 70 Carboplatin Paclitaxel 70 Daptomycin 70 NS5B polymerase 70 Immunosuppression 70 Camptosar ® 70 Combination Therapy 70 Nitazoxanide 70 Breast Cancers 70 receiving VELCADE 70 Aurora Kinase 70 Relapsing Remitting Multiple Sclerosis 70 atypical Hemolytic Uremic Syndrome 70 Therapy Improves 70 Telbivudine 70 moderate renal impairment 70 bone marrow reticulin deposition 70 TNF Blockers 70 relapsing remitting MS RRMS 70 Prophylactic Treatment 70 Peginterferon Alfa 2b 70 miconazole Lauriad ® 70 cetuximab Erbitux R 70 Posaconazole 70 Phase IIb Clinical Trial 70 HBeAg negative 70 Hsp# Inhibitor 70 Initiate Phase 70 Pivotal Phase III 70 Risedronate 70 Moxifloxacin 70 Pivotal Study 70 Hepatitis C Genotype 70 Treatment Resistant 70 Clinical Trial Evaluating 70 Telithromycin 70 Anti VEGF 70 Epstein Barr Virus 70 interferon ribavirin 70 benzoic acid hyoscyamine sulfate 70 Biogen Genentech 70 GRNOPC1 contains 70 Bevacizumab 70 TO AVOID PREGNANCY WHILE 69 Microalbuminuria 69 Mouse Models 69 Diabetic Neuropathic Pain 69 Initiates Phase II 69 Clostridium Difficile Associated 69 Physical Function 69 gefitinib Iressa 69 ORLive Presents 69 INSPIRE Trial Phase III 69 Subgroup Analysis 69 Arrhythmogenic 69 Primary Hypercholesterolemia 69 ST Elevation Myocardial 69 Azacitidine 69 Study Showed 69 ACTEMRA TM 69 Brain Metastases 69 EGFr expressing metastatic colorectal 69 Circulating Tumor Cells 69 toenail onychomycosis 69 By JENNIFER LEARN 69 tumors GIST 69 Cardiac Resynchronization 69 Myelodysplastic Syndrome 69 FDA Approvals 69 HCV NS5B polymerase 69 Paraplatin ® 69 Proves Effective 69 Completes Enrollment 69 REMINDER ORLive Presents 69 valsartan amlodipine 69 Factor Receptor 69 Xelox 69 Acute Exacerbations 69 deCODE ProstateCancer TM 69 5 FU leucovorin 69 Pivotal Clinical Trial 69 Comorbidities 69 targeted radiotherapeutic 69 smoldering multiple myeloma 69 Diabetic Nephropathy 69 hypertrichosis occurred 69 oral prodrug 69 Non Invasive Treatment 69 Demonstrates Sustained 69 Alemtuzumab 69 Liver Failure 69 Leucovorin 69 Irinotecan 69 Prolongs Life 69 chemotherapy cisplatin 69 Intravenous immunoglobulin 69 reduce serum phosphate 69 evaluating tivozanib 69 Experimental Vaccine 69 developing Bicifadine serotonin 69 dexamethasone Decadron 69 tenofovir emtricitabine 69 Pemetrexed 69 Pioglitazone 69 FDA Approves Novel 69 Cyclophosphamide 69 Gamunex C 69 Chronic Myelogenous Leukemia 69 Diabetic Patients 69 Ecallantide 69 Non Alcoholic Fatty 69 Squamous Cell Carcinoma 69 Protease Inhibitors 69 Aliskiren 69 Invasive Breast Cancer 69 Demonstrate Significant 69 trastuzumab Herceptin ® 69 Tiotropium 69 Antigen Specific 69 orally administered synthetic retinoid 69 Gene Variant 69 Neoadjuvant Chemotherapy 69 Antiangiogenic 69 Cognitive Deficits 69 metastatic neuroendocrine tumors 69 Epoetin Alfa 69 Darunavir 69 Bisphosphonate 69 Epidermal Growth Factor Receptor 69 Septic Shock 69 HIV treatments Reyataz 69 Double Blind Placebo 69 cisplatin gemcitabine 69 Benign Prostatic Hyperplasia 69 hypereosinophilic syndrome 69 hyperphenylalaninemia HPA due 69 Antiviral Activity 69 Humanized Anti 69 Fluticasone 69 candesartan cilexetil 69 Kinase Inhibitor 69 aripiprazole Abilify 69 Multiple Myeloma Patients 69 Atripla combines 69 albiglutide 69 Pulmonary Arterial Hypertension 69 Bayer HealthCare Onyx Pharmaceuticals 69 Endothelial Cells 69 Pertuzumab 69 Kidney Function 69 Lipodystrophy 69 Prostate Cancer Vaccine 69 Oral Anticoagulant 69 Basal Cell 69 Daclizumab 69 Effectively Treats 69 novel VDA molecule 69 Fungal Infections 69 Severe Asthma 69 aplastic anemia AA 69 Fewer Side Effects 69 Granted Orphan Drug 69 Carotid Stenting 69 Treatment Naïve Patients 69 Acute Ischemic Stroke 69 Adjuvant Therapy 69 candidates Azedra TM 69 pralatrexate injection folate analogue 69 Nicotine Vaccine 69 Bone Marrow Transplants 69 discontinued Viread 69 Stomach Cancer 69 Lubiprostone 69 Vicriviroc 69 FOLFOX6 chemotherapy regimen 69 Expanded Indication 69 candidemia 69 Gene Mutation Linked 69 Successfully Completes Phase 69 PROCRIT ® 69 Hypercholesterolemia 69 Golimumab 69 Initiates Phase III 69 relapsed leukemia 69 Files IND 69 Cell Non Hodgkin 69 Darapladib 69 metaglidasen 69 Immunomodulatory 69 Gene Mutations 69 Anticancer Activity 69 Omacetaxine 69 Placebo Controlled Trial 69 Glufosfamide 69 non nucleoside inhibitor 69 Physician Insights 69 Cancer Patients Treated 69 Premature Infants 69 included exfoliative dermatitis 69 Antiviral Therapy 69 Navelbine ® 69 Own Stem Cells 69 Maribavir 69 Bivalirudin 69 Mycophenolate Mofetil 69 Systemic Sclerosis 69 vaginal candidiasis 69 Metastatic Renal Cell Carcinoma 69 Vaccine Protects Against 69 Overactive Bladder 69 Malignant Melanoma 69 Less Invasive 69 nevirapine Viramune 69 Ozarelix 69 Patient Enrollment 69 Signaling Pathway 69 Generalized Anxiety Disorder 69 DEB# 69 Wafer polifeprosan 69 5 HT4 69 Breast Tumors 69 non porcine pancreatic 69 Bortezomib 69 Skeletal Muscle 69 Sangamo BioSciences Announces 69 AFREZZA TM 69 Squamous 69 Platinol ® 69 Visceral Fat 69 Statin Therapy 69 Initiate Phase III 68 Reduces Mortality 68 8mg/kg 68 MYCAMINE 68 protease inhibitor PI 68 Insulin Glargine 68 Potentially Fatal 68 vWD 68 Brentuximab Vedotin SGN 68 Ischemic Stroke 68 Glycemic Control 68 IMiDs ® compound 68 Diabetic Foot Ulcers 68 Spinal Fractures 68 Investigational Drug 68 Dementia Related Psychosis 68 Epstein Barr Virus EBV 68 hyperplasia BPH 68 Minimally Invasive Procedure 68 Denufosol 68 approved incretin mimetic 68 containing abacavir 68 Cell Lymphoma CTCL 68 EGFR TKI 68 topical gel formulation 68 Fluconazole 68 hypervascular tumors 68 tetracycline antibiotic 68 biologic DMARD 68 Hepatocellular Carcinoma 68 Treatment Naive 68 Acute Attacks 68 Granulocyte Colony Stimulating Factor 68 Fulvestrant 68 B Cell Lymphoma 68 abacavir lamivudine 68 Breast Cancer Cells 68 AFREZZA ™ 68 achieved CCyR 68 PEGINTRON TM 68 NDA Submission 68 Clinically Significant 68 Deforolimus 68 Provectus Pharmaceuticals specializes 68 Polyneuropathy 68 Recombinant Human 68 Increased Mortality 68 Catheter Ablation 68 tenofovir Viread 68 Chronic Heart Failure 68 Intravitreal injections 68 Showed Significant 68 Cognitive Function 68 trastuzumab Herceptin R 68 Chronic Lymphocytic Leukemia CLL 68 C Reactive Protein 68 Clinical Outcome 68 advanced metastatic renal 68 sulfonylurea metformin 68 GW# [003] 68 efavirenz EFV 68 Renal Function 68 chronic myeloid 68 Therapy Reduces 68 ORENCIA ® 68 Hepatic Encephalopathy 68 alpha 2a 68 Relapsed Refractory Aggressive 68 Investigational Oral 68 Improves Quality 68 oral antidiabetic medication 68 metastatic pancreatic 68 Initiates Clinical 68 non resectable metastatic 68 Epratuzumab 68 Sanofi Pasteur Fluzone 68 Zollinger Ellison Syndrome 68 Bicalutamide 68 Fludara ® 68 PegIFN RBV 68 #mg/#mg 68 Blood Thinner 68 Orally Active 68 Artery Disease 68 Regenerative Cells 68 atypical hemolytic uremic syndrome 68 Treatment Regimen 68 overt nephropathy 68 Cell Lymphoma 68 denileukin diftitox 68 including eniluracil ADH 68 Bosentan 68 Postmenopausal 68 gastrointestinal stromal tumors GIST 68 GVAX Immunotherapy 68 Organ Rejection 68 indinavir Crixivan 68 Tocilizumab 68 Advanced Renal Cell 68 Oral Calcitonin 68 Paroxysmal Nocturnal Hemoglobinuria PNH 68 receptor tyrosine kinase inhibitor 68 Lung Tumors 68 Ovitrelle R Serostim 68 Xeloda ® 68 investigational oral inhibitor 68 humanized interleukin 6 68 Submits NDA 68 Vasomotor Symptoms 68 Dendritic Cells 68 Breast Cancer Treatment 68 Cholinesterase Inhibitors 68 Anticonvulsant 68 Lung Cancer Drug 68 biliary tract cancer 68 iobenguane 68 Muscle Function 68 Shown Effective 68 Non Alcoholic Steatohepatitis 68 Insulin Resistance 68 include Healive TM 68 investigational pharmacologically unique 68 Letairis ambrisentan 68 Glucocorticoid 68 PLX STROKE targeting 68 insulin glulisine 68 Brain Lesions 68 Fixed Dose 68 pegylated interferon alfa 2a 68 gemcitabine Gemzar 68 pegylated interferon alpha 2a 68 Liver Injury 68 Ph + acute lymphoblastic 68 R metformin Concor 68 MIRAPEX ER 68 NASH Huntington 68 oropharyngeal candidiasis OPC 68 interferon beta 1a infertility 68 methylnaltrexone bromide 68 Synthetic Peptide 68 Non Responders 68 Randomized Study 68 Tezampanel 68 targeting miR 68 K ras mutations 68 beta 1a 68 cell carcinoma RCC 68 Mitoxantrone 68 Oral Cladribine 68 Inhaled Nitric Oxide 68 serologically active systemic lupus 68 Colorectal Adenomas 68 First Patient Enrolled 68 Osteoarthritis Patients 68 aflibercept VEGF Trap 68 Viagra Soft Cialis Soft 68 nicardipine 68 myelofibrosis polycythemia vera 68 Respiratory Virus 68 Gleevec resistant 68 Diffuse Large B 68 Immunosuppressant 68 Occlusive Disease 68 Systemic lupus erythematosus SLE 68 gastrointestinal stromal 68 5 fluorouracil leucovorin 68 Progenitor Cells 68 Adenoma 68 Bronchopulmonary Dysplasia 68 Fondaparinux 68 AA Amyloidosis 68 MKC# MT 68 Aeolus Pharmaceuticals Announces 68 Demonstrates Potential 68 Ranibizumab 68 Papillary 68 Treating Prostate Cancer 68 Temodar ® 68 tolterodine ER 68 Pramlintide 68 metastatic GIST 68 etanercept Enbrel 68 irinotecan doxorubicin oxaliplatin paclitaxel 68 Gastrointestinal Stromal Tumors 68 Obese Patients 68 Bronchodilator 68 Drug Fails 68 Therapy Shows Promise 68 Esophagitis 68 ZOLINZA 68 fluconazole resistant 68 Retreatment 68 Antitumor 68 Folfox 68 Reduces Risk 68 BARACLUDE R 68 acetonide FA 68 Corticosteroid 68 Entry Inhibitor 68 nucleotide analogue 68 basiliximab 68 Chronic Lymphocytic Leukemia 68 substantially excreted 68 Therapeutic Efficacy 68 Zoledronic Acid 68 vascular occlusive diseases 68 vinca alkaloid 68 Therapeutic Vaccine 68 receiving XGEVA 68 Percutaneous vertebroplasty 68 Elotuzumab 68 Enzastaurin 68 Controlled Study 68 ribavirin RBV 68 Dose Ranging Study 68 Maven Semantic 68 Pharmacokinetic Study 68 R pioglitazone HCl 68 Statistically Significant 68 refractory metastatic 68 Hepatitis C Infection 68 Pegylated interferon 68 l lysine 68 Peripheral Blood 68 deCODE AF TM 68 delivers fluocinolone acetonide FA 68 invasive candidiasis 68 Copegus ribavirin 68 INCB# [003] 68 basal bolus therapy 68 Muscle Wasting 68 Syndrome HARS 68 Sipuleucel T 68 Brain Tumor Patients 68 Chemokine Receptor 68 thetreatment 68 Xenografts 68 Gene Variants 68 Renal Cell Cancer 68 Regimens 68 Regenerative Cell 68 R entecavir 68 interleukin IL -# 68 vitreous floaters 68 Nesiritide 68 Fabry Disease 68 metastatic gastric 68 Metastases 68 Vitamin D Linked 68 Bipolar Mania 68 Altera Nebulizer System 68 adefovir dipivoxil 68 3TC lamivudine 68 Vincristine 68 LHRH receptor positive 68 Chronic Bronchitis 68 Thromboembolism 68 Treat Anemia 68 elevated transaminases 68 NAVISTAR R 68 Presents Positive 68 RNAi Therapeutic 68 investigational integrase inhibitor 68 pegylated liposomal doxorubicin 68 J Am Coll 68 Hypotension 68 Placebo Controlled 68 Zovirax acyclovir 68 FDA APPROVES 68 retinal vein occlusion induced 68 ethambutol 68 Intracerebral Hemorrhage 67 Parathyroid Hormone 67 Cardiac Function 67 Kinoid 67 Talabostat 67 subependymal giant cell 67 Soluble CD# 67 Antifungal 67 Immune Cells 67 Bucindolol 67 Methylnaltrexone 67 Sustained Reduction 67 accumulate preferentially 67 chemotherapy FOLFOX 67 Chemotherapy Improves 67 Etanercept 67 Mitomycin C 67 Orthostatic Hypotension 67 Adenomas 67 constipation OIC 67 HMG CoA reductase inhibitors 67 Localized Prostate Cancer 67 Brain Atrophy 67 Cannabinor 67 Doxil ® 67 gastrin analogue TT 67 Dupuytren Disease 67 Colorectal Cancer Patients 67 cromolyn sodium 67 Liprotamase 67 Radical Prostatectomy 67 efalizumab 67 Phospholipase A2 67 Randomized Clinical Trials 67 receiving immunosuppressive therapy 67 non peptidic protease 67 meropenem 67 SSc 67 Newly Diagnosed 67 JAK2 Inhibitor 67 Antifungals 67 Testosterone Therapy 67 Skin Lesions 67 Healthbeat Report 67 Attenuates 67 leukemia multiple myeloma 67 Atomoxetine 67 Didanosine 67 AGILECT R 67 Uterine Fibroid Embolization 67 steroid refractory ulcerative 67 Sevelamer 67 Intravenous Formulation 67 pharmacologically active isomer 67 Preclinical Data 67 Hyperphosphatemia 67 Myocardial Perfusion Imaging 67 BENLYSTA TM 67 Psoriasis Drug 67 Lymphoid 67 AZT zidovudine Retrovir 67 Receives Approvable Letter 67 Paliperidone ER 67 metastatic colorectal 67 Gout Drug 67 Prove Effective 67 Teriparatide 67 Pfizer Camptosar 67 Plaquenil 67 Chronic lymphocytic leukemia 67 metastatic colorectal carcinoma 67 forodesine 67 DG# compounds targeting 67 Submits Biologics License Application 67 Doripenem 67 Hormone Replacement 67 Tolerability 67 pegylated interferon alpha 67 External Beam 67 Anticancer Drugs 67 venlafaxine Effexor 67 Platelet Inhibition 67 Genetic Variant 67 Antidepressants Linked 67 Commonly prescribed 67 phenyl salicylate methylene blue 67 Simulect 67 cytomegalovirus retinitis 67 nilotinib Tasigna ® 67 AAG geldanamycin analog 67 Liver Tumors 67 Elagolix 67 azilsartan medoxomil 67 Adjuvanted 67 Innate Immune 67 Lowers Blood Pressure 67 Olaparib 67 Antihypertensive 67 Transplant Rejection 67 D aspartate NMDA receptor 67 MyVax R 67 Parnate 67 lexidronam injection 67 Launches Generic Version 67 Ondansetron Injection USP 67 Bevacizumab Avastin 67 Carcinomas 67 Medoxomil 67 cisplatin chemotherapy 67 brivanib 67 Critically Ill Patients 67 Chronic Pelvic Pain 67 Glioblastoma Multiforme 67 psoriatic arthritis PsA 67 patients coinfected 67 FOLOTYN ® 67 MAGE A3 ASCI 67 Romidepsin 67 Intravascular 67 either acutely decompensated 67 R bisoprolol Euthyrox 67 Endometrial Cancer 67 Allergic Rhinitis 67 undergoing elective percutaneous 67 MGd 67 Proven Effective 67 echinocandin 67 monoclonal antibody conjugated 67 Copegus ® 67 Adalimumab